BioCryst Pharmaceuticals Inc. (BCRX)
$9.88
$0.18
(1.80%)
As on 01-Sep-2026 15:38EDT
Market cap
$2,509 Mln
Revenue (TTM)
$941 Mln
P/E Ratio
--
P/B Ratio
56.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-19.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
7.2
-
Debt to Equity
-1.7
-
Book Value
$--
-
EPS
$-1.5
-
Face value
--
-
Shares outstanding
255,535,105
10 Years Aggregate
CFO
$-864.76 Mln
EBITDA
$-966.64 Mln
Net Profit
$-1,284.74 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BioCryst Pharmaceuticals (BCRX)
| 26.6 | 10.0 | 10.8 | 18.8 | 11.6 | -9.1 | 9.2 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
BioCryst Pharmaceuticals (BCRX)
| 3.7 | 25.3 | -47.8 | -17.1 | 85.9 | 115.9 | -57.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BioCryst Pharmaceuticals (BCRX)
|
9.9 | 2,509.4 | 940.6 | -384.7 | -32.8 | -- | -- | 56.6 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.7 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 361.2 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 539.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 584.5 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 351.0 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout BioCryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the... treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Read more
-
CEO, President & Executive Director
Mr. Jon P. Stonehouse
-
CEO, President & Executive Director
Mr. Jon P. Stonehouse
-
Headquarters
Durham, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for BioCryst Pharmaceuticals (BCRX)
What is the current share price of BioCryst Pharmaceuticals Inc (BCRX) Today?
The share price of BioCryst Pharmaceuticals Inc (BCRX) is $9.88 (NASDAQ) as of 01-Sep-2026 15:38 EDT. BioCryst Pharmaceuticals Inc (BCRX) has given a return of 11.57% in the last 3 years.
What is the current PB & PE ratio of BioCryst Pharmaceuticals Inc (BCRX)?
Since, TTM earnings of BioCryst Pharmaceuticals Inc (BCRX) is negative, P/E ratio is not available.
The P/B ratio of BioCryst Pharmaceuticals Inc (BCRX) is 56.59 times as on 28-Aug-2026, a 992 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
6.48 |
-14.35 |
2024 |
-17.55 |
-3.28 |
2023 |
-5.33 |
-2.65 |
2022 |
-8.68 |
-7.28 |
2021 |
-13.68 |
-23.54 |
What is the 52 Week High and Low of BioCryst Pharmaceuticals Inc (BCRX)?
The 52-week high and low of BioCryst Pharmaceuticals Inc (BCRX) are Rs 11.22 and Rs 6.00 as of 02-Sep-2026.
What is the market cap of BioCryst Pharmaceuticals Inc (BCRX)?
BioCryst Pharmaceuticals Inc (BCRX) has a market capitalisation of $ 2,509 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in BioCryst Pharmaceuticals Inc (BCRX)?
Before investing in BioCryst Pharmaceuticals Inc (BCRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.